DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pancreatitis — screening already-approved drugs against its 13-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePancreatitis maps to a 13-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pancreatitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase non-receptor type 11 (PTPN11) — PTPN11 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4GWF · 2.1 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts describe pancreatitis as a difficult research problem. In 1999, the authors stated that identifying the molecular mechanisms of acute and chronic pancreatitis in humans is one of the most difficult problems in modern science, citing obstacles including the inaccessibility of the human pancreas, unpredictability of disease onset, inability to biopsy safely, and difficulty distinguishing initiating events from the inflammatory response. Animal models were noted to fail to provide critical insights partly because of the artificial methods used to induce pancreatitis. A 2001 review noted that differentiating chronic pancreatitis from pancreatic cancer remains a great challenge. A 2004 review stated that diagnosis of early chronic pancreatitis remains challenging and that a rapid diagnostic test combining endoscopy and direct stimulatory testing was not ready for clinical use.
Genetic discoveries are reported. A 1999 paper reported that mutations in the cationic trypsinogen gene responsible for hereditary pancreatitis had been found in American and European kindreds. A 2002 review stated that a mutation in the cationic trypsinogen gene (R122H) resulting in a gain of trypsin function was found in most patients with hereditary pancreatitis, and that other mutations in that gene, in the gene for pancreatic secretory trypsin inhibitor, in the cystic fibrosis gene encoding a chloride channel, and in genes for ethanol-metabolising enzymes had been linked to chronic pancreatitis. The 2002 review concluded that recent data suggest genetics may play a role in the pathogenesis of pancreatitis. A 2001 paper noted that an epidemiological link between chronic pancreatitis and pancreatic cancer had been established.
Regarding inflammation and potential targets, a 2015 review reported that animal model and limited human studies had identified immune signalling molecules including toll-like receptors, high mobility group box 1, and IL-33 in acute pancreatitis. In chronic pancreatitis, a critical role for macrophage-pancreatic stellate cell interaction was described as a potential targetable pathway that can alter fibrogenesis. The 2004 review noted that investigation of stellate cells, an essential component of fibrogenesis, had led to identification of potential novel treatments for chronic pancreatitis, but that well-designed, controlled studies were needed. The 2004 review also stated that steroids were an effective treatment for autoimmune pancreatitis, a specific form of chronic pancreatitis. The 2015 review noted that microbiome research in pancreatitis is a new field requiring further investigation.
What is still missing: well-designed, controlled studies for any novel treatment targeting stellate cells or immune signalling; a reliable method for early diagnosis of chronic pancreatitis; a clear distinction between initiating events and the inflammatory response in human tissue; and a validated understanding of the microbiome’s role. The fundamental question of whether pancreatitis begins in the acinar cell or through duct pathology remains debated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Gastroenterology · 2015 · 211 citations · open access
Inflammation in acute and chronic pancreatitis
AbstractPURPOSE OF REVIEW: This report reviews recent animal model and human studies associated with inflammatory responses in acute and chronic pancreatitis. RECENT FINDINGS: Animal model and limited human acute and chronic pancreatitis studies unravel the dynamic nature of the inflammatory processes and the ability of the immune cells to sense danger and environmental signals. In acute pancreatitis, such molecules include pathogen-associated molecular pattern recognition receptors such as toll-like receptors, and the more recently appreciated damage-associated molecular pattern molecules or 'alarmin' high mobility group box 1 and IL-33. In chronic pancreatitis, a recent understanding of a critical role for macrophage-pancreatic stellate cell interaction offers a potential targetable pathway that can alter fibrogenesis. Microbiome research in pancreatitis is a new field gaining interest but will require further investigation. SUMMARY: Immune cell contribution to the pathogenesis of acute and chronic pancreatitis is gaining more appreciation and further understanding in immune signaling presents potential therapeutic targets that can alter disease progression.
Differentiation of Chronic Pancreatitis from Pancreatic Cancer: Recent Advances in Molecular Diagnosis
AbstractChronic pancreatitis is an inflammatory disease of the pancreas, characterized by a progressive destruction of the exocrine and endocrine pancreas, leading both to exocrine and endocrine insufficiency. In recent years, our knowledge of this disease has improved, an epidemiological link between chronic pancreatitis and pancreatic cancer has been established, and the molecular alterations underlying their pathogenesis have been partly revealed. Nevertheless, the differentiation of chronic inflammation of the pancreas from cancer of the pancreas remains a great challenge. This overview will point out the present knowledge of the molecular pathogenesis of chronic pancreatitis and pancreatic cancer and will focus on the role of molecular markers for differentiating chronic pancreatitis from pancreatic cancer.
AbstractSee article on page 259
Identifying the molecular mechanisms responsible for acute and chronic pancreatitis in humans is one of the most difficult problems in modern science. Major obstacles include the inaccessibility of the human pancreas to observation, the unpredictability of disease onset, the non-specific nature of abdominal pain early in the course of acute pancreatitis, an inability to biopsy the pancreas safely, difficulty in distinguishing initiating events from the concomitant inflammatory response, and the obvious problems of investigating a tissue that self-destructs during the disease process. Even fundamental questions as to whether pancreatitis begins in the acinar cell or through pathology related to the pancreatic ducts continue to be debated.1 2 Animal models also fail to provide critical insights, partly because of the artificial methods used to induce pancreatitis.3-5
The discovery of the mutations in the cationic trypsinogen gene responsible for hereditary forms of pancreatitis in American and European kindreds6 7 provided tremendous insights into the mechanism of acute and chronic pancreatitis …
Scandinavian Journal of Gastroenterology · 2002 · 10 citations
Genetic Basis of Chronic Pancreatitis
AbstractBACKGROUND: Pancreatitis has a proven genetic basis in a minority of patients. METHODS: Review of the literature on genetics of pancreatitis. RESULTS: Ever since the discovery that in most patients with hereditary pancreatitis a mutation in the gene encoding for cationic trypsinogen (R122H) was found that results in a gain of trypsin function', many other mutations in the cationic trypsinogen gene, as well as in the gene encoding for pancreatic secretory trypsin inhibitor, have been found in patients with chronic pancreatitis. Furthermore, mutations in other genes, like the mucoviscoidosis-gene encoding for a chloride channel, and in genes encoding for enzymes involved in the metabolism of ethanol, have been linked to chronic pancreatitis. This article reviews the highlights that have been achieved in this field of pancreatic research. CONCLUSIONS: Recent data suggest that genetics may play a role in the pathogenesis of pancreatitis.
Current Opinion in Gastroenterology · 2004 · 7 citations
Chronic pancreatitis
AbstractPURPOSE OF REVIEW: Clinicians are learning more about chronic pancreatitis but are entering an era of some confusion, primarily driven by uncovering new etiologies of chronic pancreatitis. Ideally, this knowledge will lead to better diagnosis and treatment, and abandonment of ill-conceived treatments. In contrast with previous reviews, this review highlights select contributions this year that may develop into true advances in chronic pancreatitis. RECENT FINDINGS: Small steps have been made to understand better the molecular basis of chronic pancreatitis. Diagnosis of early chronic pancreatitis remains challenging. Rapid diagnosis by combining endoscopy and a direct stimulatory test of pancreatic function may lead to more widespread use of function testing, but this test is not ready for clinical use. Application of microarray and proteomic technologies may aid future diagnosis of chronic pancreatitis. The failure to account clearly for the phenotype of patients with chronic pancreatitis may confound delineating the etiologies of chronic pancreatitis. Clinical description and studies of autoimmune pancreatitis have led to the realization that steroids are an effective treatment for this form of chronic pancreatitis. Genetic-based studies have provided insight into the pathogenic mechanisms of chronic pancreatitis. Investigation of the role of stellate cells, an essential component fibrogenesis, has led to identification of potential novel treatments for chronic pancreatitis. SUMMARY: Ongoing basic and clinical research this past year has characterized further the histologic, genetic, molecular, and clinical aspects of chronic pancreatitis, efforts that may translate into novel therapies once well-designed, controlled studies have been performed.
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · 2001 · 2 citations
Pathogenetische Konzepte der chronischen Pankreatitis
AbstractSummary. The understanding of the pathogenesis of chronic pancreatitis is limited. Several theories (i. e. obstruction hypothesis) were suggested in the past but could not be confirmed by experimental data. As a formal description of the course of the disease, the necrosis-fibrosis concept seems to be very attractive. According to this theory, there is no significant difference in the pathogenesis of acute and chronic pancreatitis. A major step was the identification of mutations of the cationic trypsinogen, the secretory trypsin inhibitor (SPINK 1) and the cystic-fibrosis protein (CFTR) in some patients. Investigation of these mutations may significantly contribute to a better understanding of the pathogenesis of chronic pancreatitis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
